Influence of SLC22A1 gene polymorphisms on gastrointestinal adverse effects with metformin therapy in South Indian type 2 diabetes mellitus patients
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20240383Keywords:
Gastrointestinal adverse effects, Metformin, rs628031, rs622342, SLC22A1, South India, T2DMAbstract
Background: Metformin, a first-line agent in Type 2 diabetes mellitus, causes gastrointestinal adverse effects in 20-30% of patients, leading to discontinuation in 5-10% of them. Organic cation transporter 1 (OCT1) encoded by SLC22A1, transports metformin from the enterocytes into the bloodstream. Reduced function OCT1 variants could lead to increased luminal concentration of metformin leading to gastrointestinal adverse effects. Two single nucleotide polymorphisms in the SLC22A1 gene were studied in this cross-sectional study with cases and controls. Objective was to determine the association between genetic polymorphisms rs628031 (1222A>G) and rs622342 (1386C>A) in SLC22A1 gene and gastrointestinal adverse effects to metformin therapy in South Indian type 2 diabetes mellitus patients.
Methods: The study was conducted in JIPMER, Puducherry, India in T2DM patients (n=300) of South Indian origin, who were categorized into case (N=100) and control (N=200) groups, based on their gastrointestinal tolerance to metformin. DNA was extracted from the patients using whole blood by phenol-chloroform method and genotyping was done using real-time PCR.
Results: Minor allele frequency of rs628031 (A allele) and rs622342 (C allele) were 33.8% and 26.5% respectively. Genotype frequencies did not differ significantly between the case and control groups (rs628031, p=0.45, rs622342, p=0.28). Female gender (AOR 3.77; 95% CI 2.07, 6.85; p<0.001) and proton pump inhibitor usage (AOR 7.66; 95% CI 3.01, 19.47; p<0.001) had higher association with metformin intolerance.
Conclusions: No significant association was found between the genotypes of single nucleotide polymorphisms (rs628031 and rs622342) in the SLC22A1 gene and gastrointestinal adverse effects to metformin therapy in South Indian type 2 diabetes mellitus patients.
References
International Diabetes Federation. Network. Available at: https://www.idf.org/our-network/regions-members/ south-east-asia/members/94-india. Accessed on 19 December 2022.
Devarajan TV, Venkataraman S, Kandasamy N, Oomman A, Boorugu HK, Karuppiah SKP, et al. Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial-START study. Indian J Endocrinol Metab. 2017;21:745-50.
American Diabetes Association. Pharmacological Approaches to Glycemic Treatments. Diab Care. 2019;42(1):S90-102.
Zhou K, Donnelly L, Yang J, Li M, Deshmukh H, Van Zuydam N, et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diab Endocrinol. 2014;2:481-7.
Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754-61.
Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diab Care. 1999;22:925-7.
Florez H, Pan Q, Ackermann RT, Marrero DG, Barrett-Connor E, Delahanty L, et al. Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012;27:1594-601.
Dawed AY, Zhou K, van Leeuwen N, Mahajan A, Robertson N, Koivula R, et al. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. Diab Care. 2019; 42:1027-33.
Dujic T, Zhou K, Yee SW. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. Clin Pharmacol Ther. 2017;101:763-72.
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577-85.
National Center for Biotechnology Information. Genetic testing Registry, SLC22A1. Available at: https://www.ncbi.nlm.nih.gov/gtr/genes/6580/. Accessed on 19 December 2022.
Tarasova L, Kalnina I, Geldnere K, Bumbure A, Ritenberga R, Nikitina-Zake L, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacog Genom. 2012;22:659-66.
Homo sapiens, Population genetics. rs628031 (SNP). Available at: http://asia.ensembl.org/Homo_sapiens/ Variation/Population?db=core;r=6:160139313-160140313;v=rs628031;vdb=variation;vf=57903835. Accessed on 19 December 2022.
Homo sapiens. Population genetics rs622342 (SNP). Available at: http://asia.ensembl.org/Homo_sapiens/ Variation/Population?db=core;r=6:160151334-160152334;v=rs622342;vdb=variation;vf=57900195. Accessed on 19 December 2022.
Han T (Kevin), Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR. Four Cation-Selective Transporters Contribute to Apical Uptake and Accumulation of Metformin in Caco-2 Cell Monolayers. J Pharmacol Exp Ther. 2015;352:519-28.
Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, et al. Clinical Pharmacokinetics of Metformin. Clin Pharmacokinet. 2011;50:81-98.
Proctor WR, Ming X, Bourdet D, Han T (Kevin), Everett RS, Thakker DR. Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis. J Pharm Sci. 2016;105:484-96.
Zhou Y, Ye W, Wang Y. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. Int J Clin Exp Pathol. 2015;8:9533-42. Umamaheswaran G, Praveen RG, Arunkumar AS, Das AK, Shewade DG, Adithan C. Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian J Hum Genet. 2011;17:164-8.
Umamaheswaran G, Praveen RG, Damodaran SE. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 2015;15:511-7.
Schwartz S, Fonseca V, Berner B. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diab Care. 2006;29:759-64.
Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43.
Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CNA, Pearson ER. Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015;64:1786-93.
Mehta SR, Kashyap AS, Das S. Diabetes Mellitus in India: The Modern Scourge. Med J Armed Forces India. 2009;65:50-4.
Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430-40.
Graff J, Brinch K, Madsen JL. Gastrointestinal mean transit times in young and middle‐aged healthy subjects. Clin Physiol. 2001;21:253‐9.
Nandhra, GK, Mark, EB, Di Tanna, GL. Normative values for region‐specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3D‐Transit electromagnet tracking system: Influence of age, gender, and body mass index. Neurogastroenterol Motil. 2019;2:e13734.
Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF. Intestinal Microbiota Is Influenced by Gender and Body Mass Index. PLoS One. 2016;11:e0154090.
Hermans MP, Ahn SA, Rousseau MF. What is the phenotype of patients with gastrointestinal intolerance to metformin? Diab Metab. 2013;39:322-9.
Staller K, Thurler AH, Reynolds JS, Dimisko LR, McGovern R, Skarbinski KF, et al. Gabapentin Improves Symptoms of Functional Dyspepsia in a Retrospective, Open-label Cohort Study. J Clin Gastroenterol. 2019;53:379-84.
